Biologic molecules, such as proteins and monoclonal antibodies, are transforming the current pharmaceutical landscape with respect to targeted medicines.
These therapeutic agents include recombinant proteins, monoclonal antibodies, fusion proteins, have a high–molecular weight and are inherently more complex than peptides or small molecules. They have transformed treatment options for patients in areas such as oncology, immunology, and rare diseases because they offer highly targeted and specific mechanisms of action. However, their structural complexity, sensitivity and large size make them challenging to formulate with traditional LAI delivery systems like PLGA.
At InnoCore, our SynBiosys® platform is expertly designed to formulate and protect these delicate biological active ingredients, enabling sustained-release delivery that preserves activity, optimizes bioavailability, and enables novel clinical formulations.
SynBiosys® overcomes the typical issues associated with Biologicals, such as aggregation and degradation due to lingering acidic moieties, enabling the formulation and delivery of these large APIs into long-acting injectable dosage forms that retain their structural and biological integrity.
Examples of biologics
Biologics offer unparalleled precision in treating diseases compared to many small molecules. Their targeted biological activity makes them ideal candidates for treating chronic and severe illnesses such as cancer, autoimmune disorders, and neurological conditions. However, their large size, structural complexity, and sensitivity under physiological conditions pose significant formulation and delivery challenges, including stability, immunogenicity, and rapid clearance.
InnoCore’s SynBiosys® drug delivery platform overcomes these hurdles by encapsulating biologics within a biodegradable polymer matrix that swells in an aqueous environment, releasing the active ingredient by controlled diffusion over time.
The technology supports multiple formulation formats—including microspheres, implants, and coatings, each designed to preserve the structural integrity of proteins, antibodies, and fusion molecules. By mitigating factors like enzymatic degradation, having no accumulation of acidic degradation products and controlled release characteristics , SynBiosys® ensures that biologics retain their integrity and therapeutic potency throughout manufacturing, scale-up and delivery.
SynBiosys® offers unmatched versatility across biologic types:
InnoCore’s strength lies not just in technology, but in end-to-end execution. We guide our programs from feasibility and formulation to scale-up, analytical characterization, and manufacturing. Our multidisciplinary team and facility ensure seamless integration of SynBiosys® into clinical pipelines, helping our partners overcome delivery challenges and accelerate therapeutic success.
Biologics represent a powerful and growing class of therapeutics, but without effective delivery tools, their potential remains limited. InnoCore’s SynBiosys® platform stands uniquely equipped to enable sustained, stable, and customizable delivery of these sensitive biologics. Backed by scientific rigor, formulation expertise, and flexible manufacturing capabilities, SynBiosys® offers a trusted pathway to transforming complex biologic therapies into patient-friendly, high-impact medicines.
"*" indicates required fields